According to Invion, the company has successfully completed the first stage of feasibility studies for its INV102 inhaled nadolol, which it intends to develop for the treatment of asthma, COPD, and cystic fibrosis. Invion is partnered with 3M Drug Delivery Systems for development of INV102 and INV104, inhaled zafirlukast.
Nadolol is a beta blocker normally used for the treatment of hypertension. Invion is also developing oral nadolol for the treatment of mild asthma and for smoking cessation in COPD patients.
Invion Executive VP and Chief Medical Officer Mitchell Glass commented, “We are very pleased with progress towards developing an inhaled version of INV102. This program, which is supported by data emerging from our current oral dosing Phase 2 clinical trials, is anticipated to significantly broaden the potential of INV102 as a treatment for chronic inflammatory airway disease and establish INV102 as an attractive medical and commercial proposition.”
Read the Invion press release.
